- Pharma Contract Templates
- MedTech Contract Templates
- Costing Tool
- Standardised Indemnity
- Decentralised Clinical Trials SOPs
Standardised Clinical Trials Research Agreements (sCTRA)
The New Zealand Association of Clinical Research (NZACRes) has developed a standardised Clinical Trial Research Agreement (sCTRA) based on the Medicines Australia template that has successfully been used in Australia. More recently NZACRes has consulted widely with the New Zealand clinical research industry to update the standardised Clinical Trial Research Agreement.
NZACRes aims to assist members and the NZL research community by providing standard templates and tools. In providing standard templates and tools NZACRes accepts no liability for any disputes arising from the use of these documents.
Updates to the CTRA’s
The standardised Clinical Trial Research Agreement (sCTRA) have been updated for alignment with the Privacy Act 2020.
Collaborative or Cooperative Groups
Contract Addendum Template
Site Personnel Privacy Consent – optional use
CTRA Indemnity Te Whatu Ora Guidance
Updates to the CIRA’s
The standardised Clinical Investigation Research Agreement (sCIRA) have been updated for alignment with the Privacy Act 2020.
Updates to the CIRA’s
- In March 2021, the standardised Clinical Investigation Research Agreement (sCIRA) have been updated for alignment with the Privacy Act 2020.
- The Sponsor and CRO sCIRA’s were updated in June 2021 to remove the reference to the Medicines New Zealand Guidelines on Clinical Trials Compensation for Injury Resulting From Participation in an Industry-Sponsored Clinical Trial in relation to participant compensation for Medical Technology studies.
Collaborative or Cooperative Groups
CIRA Addendum Template
Privacy Consent – for optional use
Costing Tool
NZACRes aims to assist members and the NZL research community by providing standard templates and tools. In providing standard templates and tools NZACRes accepts no liability for any disputes arising from the use of these documents.
The costing tool is an Excel spreadsheet template that can be used by sites to facilitate accurate trial costing and to support transparent price discussion.
Download here:
NZ Clinical Research costing tool v1.4 Mar 2017 (109 KB)
NZ Clinical Research costing tool Summary of Changes v1.4 Mar 2017 (210 KB)
Why was it created?
What types of trial can I use the tool for?
How does the tool add value?
- provides all parties in the clinical trials industry with a clear and consistent understanding of what the various components and terms involved in costing for clinical trials mean
- gives research teams and their organisations a clear and accurate picture of the financial implications of conducting a trial so that decisions can be made based on sound information
- gives consistency to the trial costing exercise, and improves efficiency as sites become familiar with the tool and can cost studies faster and more accurately
- provides a baseline against which actual trial costs can be compared as the trial runs to completion
- speeds up the budget negotiation process by ensuring all site costs are calculated at the outset, and site costs are consistent from one trial to the next
- is sufficiently uncomplicated (despite the complexity of clinical trial costing) that it can be used by busy research teams whether or not there is dedicated assistance and support within the organisation
- includes a summary of costs page that can be used during the site approval/signing stage
It is not a compulsory instrument; it is intended as a helpful tool which will streamline site budgeting processes and provide a common financial ‘language’ for clinical trial costing. Also, it is not intended that the costing tool replaces sponsor-site budget discussions and negotiations. It is an in-house document only which will allow sites to see where their costs lie.
How is it maintained?
How do I use the costing tool?
Instructions for use
Study Protocol
Evidence of costs
Support and guidance
Standardised Indemnity & Compensation Agreements (sICA)
After consultation with Pharmaceutical companies, CROs, DHBs and Universities, a standard Indemnity and Compensation Agreement (sICA) was created and released in November 2009. The sICA has been updated since initial release.
NZACRes aims to assist members and the NZL research community by providing standard templates and tools. In providing standard templates and tools NZACRes accepts no liability for any disputes arising from the use of these documents.
Cancer Decentralised Clinical Trial (DCT) methodology
Clinical trials are essential to improving outcomes for patients with cancer. Opportunities for participation in clinical trials across Aotearoa New Zealand are inequitable, particularly for whānau living outside of major centres and for Māori and Pasifika. The implementation of decentralised clinical trials aims to increase access to clinical trials for people with cancer living across Aotearoa New Zealand. In the decentralised clinical trial model the primary trial site(s) work collaboratively with sites in smaller centres and rural areas (satellite sites) to enrol, consent and treat patients for the trial. Decentralised clinical trials essentially aim to increase access to clinical trials by decentralising the processes of a clinical trial. This can include consent, randomisation, delivery of investigational products, trial activity, data entry and potentially trial monitoring. Decentralised clinical trials give patients and whānau the opportunity to participate in clinical trials without the requirement for travel, which comes at a financial cost to both patients and the healthcare system. It also allows patients to continue to receive care locally (which can be in person), without removing them from their whānau and support systems. This makes trials more inclusive, accessible and whānau-centred.
The National Oncology Decentralised Clinical Trial Steering Committee, with financial support from Te Aho o Te Kahu, has overseen the development of processes and procedures and ensured that the development of decentralised clinical trial methodology is appropriate and relevant for whānau Māori and Aotearoa New Zealand.
The following documents (SOPs, supervision plan, terms of reference) have been developed by and are the responsibility of the National Oncology Decentralised Clinical Trial Steering Committee, not NZACRes. Any queries should be directed to the National Oncology Decentralised Clinical Trial Steering Committee co-lead Dr Nicky Lawrence: nicky.lawrence@auckland.ac.nz